<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866944</url>
  </required_header>
  <id_info>
    <org_study_id>MT201-204</org_study_id>
    <nct_id>NCT00866944</nct_id>
  </id_info>
  <brief_title>Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases</brief_title>
  <acronym>MT201-204</acronym>
  <official_title>A Randomized, Open-label, Controlled, Multi-center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen Research (Munich) GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen Research (Munich) GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of adecatumumab alone or following
      FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to
      compare the effect to FOLFOX alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival rate (DFS)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to relapse</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adecatumumab alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX 4 followed by Adecatumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX 4 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adecatumumab</intervention_name>
    <description>Adecatumumab,6-9mg/kg, every 14 days, 24 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MT201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adecatumumab and FOLFOX</intervention_name>
    <description>FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX 4</intervention_name>
    <description>FOLFOX 4, every 14 days, 12 cycles</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed complete resection (R0) of liver metastases from
             colorectal adenocarcinoma

          -  Age ≥18 years

          -  ECOG performance status ≤ 2

          -  Patient was informed, has read and understood the patient information / informed
             consent form and has given written informed consent

        Exclusion Criteria:

          -  Extra-hepatic distant metastases or locally recurrent disease at time of enrolment

          -  Neoadjuvant chemotherapy of liver metastases prior to surgery

          -  Any anticancer chemotherapy within 4 weeks prior to study entry

          -  Start of Oxaliplatin-based chemotherapy within 9 months prior to study entry

          -  Any biological anticancer therapy or immunotherapy within 4 weeks prior to study entry

          -  Any radiotherapy or radio frequency ablation (RFA) to the liver prior to surgery

          -  Treatment with any investigational product within a time range of 4-5 half-lives (t½)
             prior to study entry

          -  Acute or chronic pancreatitis or history of alcohol induced pancreatitis

          -  Liver cirrhosis, acute hepatitis or chronic hepatic disease

          -  Any unresolved complications from prior surgery

          -  Persistent neuropathy

          -  History of other malignancy within 5 years prior to study start, with the exception of
             basal cell carcinoma of the skin, carcinoma in situ of the cervix and Ductal Carcinoma
             in Situ (DCIS)

          -  History of inflammatory bowel disease

          -  Active severe infection, any other concurrent disease or medical condition that is
             deemed to interfere with the conduct of the study as judged by the investigator

          -  Use of immune-suppressive agents such as the regular use of systemic corticosteroids

          -  HIV positivity

          -  Known hypersensitivity or intolerability to immunoglobulins in general, other
             recombinant human or humanized antibodies, Folinic Acid, 5-Fluorouracil, Oxaliplatin
             or a component of the study drug formulations, known dihydropyrimidine dehydrogenase
             (DPD) deficiency

          -  Pregnant or nursing women

          -  Women of childbearing potential or male patients not willing to use an effective form
             of contraception during treatment phase of the study and at least 6 months thereafter

          -  Not willing or incapable to comply with all study visits and assessments

          -  Placed into an institution due to juridical or regulatory ruling
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Neuhaus, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Campus Virchow Klinikum, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Dufour, Pr. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Strauss, Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Bruderwald, Sozialstiftung Bamberg</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Heinrich-Heine Universität</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W. Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther Universität</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes-Gutenberg Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim GmbH Universitätsklinikum</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der LMU Grosshadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Neuperlach</name>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <last_update_submitted>November 10, 2011</last_update_submitted>
  <last_update_submitted_qc>November 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal carcinoma</keyword>
  <keyword>Liver metastases (only)</keyword>
  <keyword>R0 resection</keyword>
  <keyword>R0 resection of liver metastases from colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

